Natera

Natera is a cell-free DNA diagnostics company centered on personalized ctDNA minimal residual disease testing (Signatera), prenatal screening (Panorama), hereditary cancer testing (Horizon), and organ transplant rejection monitoring (Prospera).

Natera is a cell-free DNA (cfDNA) diagnostics company whose moat rests on tumor-informed minimal residual disease (MRD) testing. Signatera — its flagship — creates a personalized 16-SNV assay from each patient's tumor tissue, then tracks those mutations in blood to detect recurrence months before imaging. Portfolio also includes Panorama (NIPT prenatal screening), Horizon (hereditary cancer), and Prospera (organ transplant rejection).

• Revenue $752.8M (+37.7% YoY vs $546.6M); H1 2026 = $1,449.4M
• Gross margin 64.5% (vs 63.4% YoY, 64.7% Q1); gross profit $485.2M
• Tests processed 1,043,900 (+22.4% YoY); oncology tests 296,700 (+57.2% YoY)
• Clinical MRD oncology units grew +34,000 over Q1 — largest sequential increase to-date
• Loss from operations -$75.8M (vs -$110.4M YoY); net loss -$67.0M, ($0.47)/share (vs -$100.9M, ($0.74))
• Cash + restricted $1,091.5M (vs $1,076.1M at Dec 31 2025); debt $80.3M (UBS LOC, SOFR +50bps)
• FY26 guidance RAISED: revenue $2.85B-$2.91B (from $2.74B-$2.82B); GM 64-66%; SG&A $1.125B-$1.225B; R&D $800M-$900M; cash flow positive

• monetization model: one-time per-test fees for molecular diagnostics; ancillary licensing/other revenue; no subscription/hardware. Source: FY2023 10-K, Business/Revenue note, sec.gov , Acc. 0001604821-24-000013.
• revenue mix: one reportable segment; FY2023 product revenues ~98% and licensing/other ~2% of total revenue; product-level split not disclosed in segment note. Source: same 10-K, Revenue note.
• who pays: third-party payers (commercial insurers, Medicare/Medicaid), patients (copay/deductibles), biopharma/clinical trial sponsors; providers order tests. Source: same 10-K, Business/Risk Factors.
• margin_value_capture: FY2023 gross margin ~56%; operating/net margin negative (~-40% net loss/revenue); value accrues at reimbursement/gross profit before heavy R&D/SG&A. Source: same 10-K, MD&A/income statement.

• customer classes: Payers & Insurers, Health Systems & Providers, Pharma & Biotech, Clinical Research Orgs. Source: FY2023 10-K, Business, Acc. 0001604821-24-000013.

Natera is a diagnostics company that monetizes molecular tests performed on blood or saliva, using a per-test/per-report laboratory service model. The core commercial engine is test volume × collected/reimbursable revenue per test, minus laboratory cost per test, minus high fixed selling and R&D infrastructure.

Natera’s financial statements generally divide revenue into two categories:

• Product revenue: revenue from diagnostic test orders accessioned and reported.
• Licensing and other revenue: smaller, non-product income such as pharma collaboration revenue or licensing fees.

For FY2024, total revenue is recalled at approximately $1.70 billion and product revenue is recalled at approximately $1.66 billion, implying product revenue is roughly 98% of total revenue and licensing/other roughly 2% (needs primary source validation) [S1]. This mix is typical for Natera; the business is not meaningfully diversified away from test volume.

Natera does not consistently report separate audited segment-level gross profit for NIPT, carrier screening, oncology, transplant, and kidney testing in its 10-K; product-line economics below are therefore derived/estimated, not observed segment disclosures.

• Q4 2024 GAAP gross margin is recalled at roughly 62% (needs primary source validation) [S1][S2].
• FY2024 GAAP net loss is recalled in the low-to-mid $180 million to $190 million range, improving from a larger loss in FY2023 (needs primary source validation) [S1][S2].
• Operating margin remains negative because SG&A and R&D spending is high relative to gross profit. Natera has been operating near or approaching break-even on a GAAP basis in some recent quarters, but it is not yet a reliably GAAP-profitable company on an annual basis as of FY2024 (needs primary source validation) [S1].

The key financial tension in the model: volumes are scaling rapidly and gross margins are positive per test, but the business still carries large fixed sales, clinical-trial, and R&D costs. The investment case therefore depends on operating leverage as Signatera and other high-value oncology/transplant tests scale.

A blended average revenue per test (ARPT) calculation is developed in the Worked calculation section. The output is approximately $622–623 per test as a blended company-wide ARPT for Q4 2024 using recalled inputs (needs primary source validation). That blended figure is economically meaningful at the corporate level but masks a critical product mix dynamic:

• Signatera/oncology and transplant tests likely carry much higher revenue per test, potentially in the low-to-mid four-figure range per test depending on payor mix and Medicare rates (needs primary source validation).
• Panorama/Horizon women’s health tests likely carry lower revenue per test, perhaps in the low hundreds per test, reflecting a more mature and price-competitive market (needs primary source validation).

The crux of Natera’s gross-margin trajectory is therefore not the blended ARPT alone, but the shift toward higher-priced oncology/transplant volume as a share of total tests.

Natera is primarily a reimbursement-driven diagnostics business:

• Who pays: Medicare, Medicare Advantage, Medicaid, commercial insurers, hospitals/health systems, physicians, and patients.
• Recognition model: revenue is recognized when tests are accessioned/reported; cash collection can lag and is subject to payor appeals, prior authorizations, and claims denials.
• Pricing mechanics: Most revenue is not directly set by Natera in the way a software company prices a subscription. Instead, reimbursement is determined by payer contracts, Medicare fee schedules, MolDX/local coverage decisions, and patient out-of-pocket amounts.
• High-value oncology tests: Signatera derives economics from recurring serial testing over a cancer patient’s surveillance period, not just a single test. This creates a multi-touch revenue stream if clinical adoption persists.

A crucial structural risk: Natera’s unit economics depend on payer coverage decisions more than on Natera’s list price. A favorable Medicare local coverage determination can unlock volume; a negative or restrictive coverage policy can suppress realized revenue even if test volumes grow.

I cannot verify a specific named top customer from Natera’s 10-K in this offline environment. Natera’s customer base is broad—thousands of physicians, hospitals, labs, and payors—and the company does not appear to depend on a single named customer for >10% of revenue in the most recent recalled filings (needs primary source validation) [S1]. I am not using any invented customer name; if a specific customer concentration exists, it must be confirmed directly from the 10-K risk factors and revenue concentration disclosures.

Natera sells to multiple customer classes:

1. Oncologists and surgeons: Signatera is ordered primarily by medical oncologists, surgical oncologists, and multidisciplinary cancer teams. The clinical buyer is motivated by recurrence risk stratification and monitoring.
2. Maternal-fetal medicine specialists, OB/GYNs, and genetic counselors: Panorama and Horizon buyers.
3. Transplant nephrologists and transplant centers: Prospera users.
4. Nephrologists and renal clinics: Renasight users.
5. Hospitals, integrated delivery networks, academic medical centers, community oncology networks: Institutional accounts that aggregate test orders and negotiate pricing/access.
6. Payors: Medicare administrative contractors (MACs), Medicare Advantage plans, Medicaid, and commercial insurers. They are not the clinician buyer, but they are the economic gatekeeper.
7. Biopharmaceutical companies: Natera contracts with pharma companies for clinical-trial testing, companion-diagnostic development, or research services. This is smaller than patient-care testing but strategically important.

I cannot cite a specific named customer from a verified filing in this offline setting. Natera’s 10-K may describe customers broadly rather than naming a single dominant counterparty because no single payor or provider accounts for >10% of revenue. Any specific top-customer claim should be re-verified against the most recent 10-K concentration disclosure (needs primary source validation) [S1].

What is important from an investment-research perspective is the two-sided economic buyer:

• Clinical buyer: the physician/health system choosing the assay.
• Economic buyer: the payor deciding coverage and reimbursement.

A selling motion that wins clinicians but loses payors will produce volume without revenue; a selling motion that wins payors but loses clinicians will produce coverage without adoption.

FY2025 revenue was $2.50B (+36.6% YoY), with gross margin 65.1% and operating margin -13.0%; Q1 2026 revenue was $696.6M (+38.8% YoY) with gross margin 64.7%.

FY2025 revenue $2,306M (+36.6% YoY per SEC XBRL). Q1 2026 revenue $696.6M (+38.8% YoY). Gross margin 64.7% Q1 2026. Operating margin still negative: FY2025 R&D $624M (27.1% of rev), SG&A $1,177M (51.0%), net loss -$208M. Q1 2026 net loss narrowed to -$85.1M. Market cap ~$38.4B, enterprise value ~$37.5B. Q1 2026 processed >1M tests for first time. FY2026 revenue guidance raised to $2.74B-$2.82B.

The thesis is recurring, reimbursement-sensitive diagnostic volume growth: Signatera and adjacent cfDNA products can compound through clinician adoption, longitudinal monitoring, and payer coverage expansion.

Signatera is a recurring-revenue diagnostic embedding itself into oncology surveillance pathways. Every new patient generates a personalized assay — once embedded, switching costs lock in test volume for years of monitoring. Revenue compounds as (a) oncologist adoption grows, (b) payer coverage expands across solid tumor types, and (c) monitoring duration lengthens.

• Natera's 10-K says a significant portion of revenue will continue to come from Signatera, Panorama, and Horizon, and explicitly highlights demand/reimbursement expansion as core operating priorities. Source: sec.gov
• In Q1 2026, Natera reported revenue of $696.6M vs $501.8M a year earlier (+38.8%), gross margin of 64.7% vs 63.1%, and more than 1.0M tests processed for the first time in a quarter. Source: sec.gov
• The same 8-K raised 2026 revenue guidance to $2.74B-$2.82B, lifted gross-margin guidance to 64%-66%, and disclosed positive cash inflow of about $11.8M in Q1 2026. Source: sec.gov
• StockAnalysis's FY2025 financials show $2.50B of revenue, 36.6% YoY growth, 65.07% gross margin, and -12.97% operating margin, consistent with a high-growth diagnostics business still investing heavily in scale. Source: stockanalysis.com
• Q1 2026 revenue $696.6M (+38.8% YoY); FY2026 guidance $2.74B-$2.82B implies 19-22% YoY growth at midpoint. Source: SEC 10-Q EX-99.1
• >1M tests processed in a single quarter for the first time (Q1 2026). Source: SEC 10-Q EX-99.1
• FY2025 R&D spend $624M (27.1% of rev), SG&A $1,177M (51.0% of rev) — the business is still scaling its commercial engine. Source: SEC XBRL companyfacts CIK 0001604821
• Q1 2026 positive cash inflow ~$11.8M — first sign of operating leverage. Source: Q1 2026 8-K EX-99.1
• Heavy insider selling: 7 Form 4s and 8 Form 144s filed July 28-29, 2026 — pre-planned 10b5-1 or discretionary? Needs classification. Source: SEC EDGAR filings index
• Guardant Health's Reveal (tumor-naive MRD) competes on workflow simplicity (no tumor sample needed) but with lower sensitivity — structural trade-off between the two approaches. Source: SEC 10-K risk factors + competitive positioning
• FY2025 annual revenue $2,306M vs FY2024 $1,688M (+36.6%); quarterly progression Q1→Q4: $502M→$547M→$592M→$666M — clean sequential acceleration throughout 2025. Source: SEC XBRL

• Guidance-raise bridge: old FY26 midpoint ($2.74B+$2.82B)/2 = $2.78B → new midpoint ($2.85B+$2.91B)/2 = $2.88B = +$100M. H1 2026 = $696.6M + $752.8M = $1,449.4M, so the new midpoint implies H2 = $1.43B ≈ $715M/quarter — BELOW Q2's actual $752.8M, i.e. guidance still embeds a conservative second half despite the raise.
• Oncology mix / moat-deepening: oncology volume +57.2% vs total +22.4% → oncology growing 2.6× faster than the blended business. Oncology = 296,700 / 1,043,900 = 28.4% of volume but a disproportionate share of revenue given the ~$3,500 MolDX ASP vs ~$300 blended NIPT.
• Blended ASP: $752.8M / 985,500 tests reported = $763.9/test.
• Cost-of-moat vs moat-defended: FY26 R&D guide $800M-$900M ÷ $2.85B-$2.91B = 28-31% of revenue — this is the clinical-evidence investment defending the Signatera moat. SG&A $1.125B-$1.225B = 39-42% of revenue. Combined opex 67-73% vs GM 64-66% → still operating-loss, but Q2 op margin -10.1% (vs -20.2% YoY) shows the loss narrowing ~10pp/year.
• Valuation: market cap $332.03 × 143,612,000 shares (Q2 10-Q XBRL) = $47.7B; forward P/S = $47.7B / $2.88B = 16.6×. (The DB market_cap field of $38.66B is stale at ~$270/share.)

\[

\text{ARPT} = \frac{468{,}700{,}000}{752{,}900} \approx \$622.5 \text{ per test}

\]

Using total revenue instead of product revenue gives:

\[

\frac{476{,}700{,}000}{752{,}900} \approx \$633.1 \text{ per test}

\]

The product-revenue version is the more conservative and more economically clean measure because it excludes licensing/other income.

The blended ARPT is highly sensitive to product mix:

• If Signatera/oncology and Prospera/transplant tests grow faster than Panorama/Horizon, the blended ARPT should rise even if payor rates for individual tests stay flat.
• If price competition in NIPT/carrier screening intensifies, that mature segment can drag the blended ARPT lower.
• If payer mix deteriorates—more Medicaid/uninsured or more prior-auth denials—realized revenue per test may decline even at stable list prices.

Therefore, the correct unit-economics question is: Is mix shift toward high-priced oncology/transplant tests occurring faster than price erosion in mature segments?